Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Capricor Therapeutics (CAPR) received an FDA Complete Response Letter on its resubmitted application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The FDA found insufficient evidence of effectiveness and cited other clinical deficiencies. Capricor said both the HOPE-2 and HOPE-3 trials met their primary endpoints.
As of September 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million. Capricor believes those funds can cover planned operations for at least the next 12 months. A conference call and webcast are scheduled for November 23 at 8:30 a.m. ET.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointHOPE-2 and HOPE-3 trials both met their primary endpoints, Capricor said
- Moderate point. Forward-looking: it has not happened yet and may not happen.Approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026, can fund planned operations for at least the next 12 months, Capricor believes
Negative
- Major pointFDA Complete Response Letter cites insufficient evidence of effectiveness and other clinical deficiencies in the resubmitted Deramiocel application
News Explained
The resubmitted BLA remains unresolved following the FDA’s Complete Response Letter; Capricor says it is reviewing the letter and will share next steps after completing that evaluation, making the review the stated path to a response.
Details
Market move: CAPR -77.60% vs previous close. Deramiocel BLA complete response letter
On Nov 20, the day this news came out, the latest delayed price for CAPR is 77.60% below the previous close. Our momentum scanner has recorded 176 alerts for this stock so far that day. The latest delayed price is $1.70. Relative volume is very high at 4.1x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Cash and marketable securities
- approximately $198.5 million
- As of September 30, 2026; includes cash, cash equivalents, restricted cash and marketable securities
- Planned operations funding
- at least the next 12 months
- Company's stated estimate based on available financial resources
Historical Context
-
HOPE-3 met its primary endpoint; secondary cardiac measure favored Deramiocel but missed statistical significance.
-
Open-label extension data showed slower upper-limb decline after placebo patients switched to Deramiocel.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
complete response letter regulatory
biologics license application regulatory
rmat regulatory
atmp regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Company receives Complete Response Letter from FDA for Deramiocel BLA
- Conference call and webcast Monday, November 23, at 8:30 a.m. ET
SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its resubmitted Biologics License Application (BLA) for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy (DMD). The CRL states that the FDA does not consider the data sufficient to establish substantial evidence of effectiveness and cites certain other clinical deficiencies.
“We are deeply disappointed for the boys and young men living with Duchenne and their families,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer. “Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval. We are reviewing the letter carefully and will share next steps once we have completed our evaluation.”
As of September 30, 2026, the Company had cash, cash equivalents, restricted cash and marketable securities of approximately
Conference Call and Webcast
To participate in the conference call, please dial 1-800-717-1738 (Domestic) or 1-646-307-1865 (International) and reference the conference ID: 27699. Participants may dial in using the numbers above and ask to be joined to the call or click the Call Me™ link for instant telephone access to the event. To participate via a webcast, please click here. A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States, primarily males. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, the leading cause of death in DMD. There is no cure, and treatment options remain limited.
About Deramiocel
Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the U.S., and Orphan Drug and ATMP designations in Europe.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; the contents of, and our response to, the Complete Response Letter and the timing of any resubmission; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval; revenue and reimbursement estimates; projected terms of definitive agreements, our financial position, cash runway and planned cost reductions, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the Securities and Exchange Commission on November 10, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.